MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Pliant Therapeutics Inc

Fechado

1.52 3.4

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.46

Máximo

1.54

Indicadores-chave

By Trading Economics

Rendimento

13M

-43M

Margem de lucro

-2,190.837

Funcionários

171

EBITDA

17M

-42M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+79.87% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-13M

91M

Abertura anterior

-1.88

Fecho anterior

1.52

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Pliant Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de out. de 2025, 20:45 UTC

Ganhos

Costco Wholesale Sales Climb in September, Early October

8 de out. de 2025, 20:12 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 de out. de 2025, 16:39 UTC

Grandes Movimentos do Mercado

Mining Shares Rise as Gold Prices Soar

8 de out. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

8 de out. de 2025, 23:43 UTC

Conversa de Mercado

Gold Falls on Possible Profit-Taking -- Market Talk

8 de out. de 2025, 23:18 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Finance Acquisition Using Internal Funds

8 de out. de 2025, 23:17 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 de out. de 2025, 23:16 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 de out. de 2025, 21:54 UTC

Conversa de Mercado
Ganhos

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 de out. de 2025, 21:30 UTC

Conversa de Mercado

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 de out. de 2025, 21:26 UTC

Conversa de Mercado
Ganhos

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de out. de 2025, 19:15 UTC

Conversa de Mercado

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 de out. de 2025, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 de out. de 2025, 18:47 UTC

Conversa de Mercado

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Will Remain a Publicly Traded Co >TASK

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 de out. de 2025, 18:07 UTC

Conversa de Mercado

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 de out. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

8 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de out. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de out. de 2025, 15:57 UTC

Conversa de Mercado

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 de out. de 2025, 15:56 UTC

Conversa de Mercado

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 de out. de 2025, 15:53 UTC

Conversa de Mercado

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 de out. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 de out. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 de out. de 2025, 15:43 UTC

Aquisições, Fusões, Aquisições de Empresas

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 de out. de 2025, 15:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparação entre Pares

Variação de preço

Pliant Therapeutics Inc Previsão

Preço-alvo

By TipRanks

79.87% parte superior

Previsão para 12 meses

Média 2.68 USD  79.87%

Máximo 4 USD

Mínimo 1.7 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

6 ratings

1

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.43 / 1.6Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat